Avextra AG, a vertically-integrated manufacturer of cannabis-based medicines located in Germany, announced the export of its standardised cannabis extracts to Italy.
Italy is a key market for Avextra, with the second-largest patient population for cannabis-based medicines in the European Union. Avextra is one of only three companies approved to import cannabis medicines into the country. According to the company in Italy over 70% of the market for cannabis-based medicines are extracts and Avextra is the first medical cannabis/pharmaceutical company to register and launch a balanced extract in Italy, by far the most sought-after potency for domestic patients.
Avextra’s co-CEO Dr. Bernhard Babel stated, "We have had extensive discussions with Italian doctors and pharmacies and see a clear need for standardised extracts in Italy. Our Italian team have regularly participated in scientific conferences and built relationships with leading researchers and clinicians and see strong potential for medical cannabis therapies to grow and develop in Italy."
Avextra's manufacturing facility in Germany adheres to strict European Union regulations, ensuring that all products meet the standards for quality and safety that EU regulators have set.
Photo by Thiago Patriota on Unsplash
Related News
Avextra AG Announces 17M Euro Capital Raise To Fuel Its Growth And Expansion Through Europe
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.